323 related articles for article (PubMed ID: 33621600)
1. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW
Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Intermittent Multidrug IV Therapy for Refractory Mycobacterium abscessus Pulmonary Disease.
Im Y; Kim SY; Kim DH; Jhun BW
Chest; 2024 Feb; 165(2):288-302. PubMed ID: 37661004
[TBL] [Abstract][Full Text] [Related]
3. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K
Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300
[TBL] [Abstract][Full Text] [Related]
4. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
[TBL] [Abstract][Full Text] [Related]
5. Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease.
Koh WJ; Jeong BH; Jeon K; Kim SY; Park KU; Park HY; Huh HJ; Ki CS; Lee NY; Lee SH; Kim CK; Daley CL; Shin SJ; Kim H; Kwon OJ
Chest; 2016 Dec; 150(6):1211-1221. PubMed ID: 27167209
[TBL] [Abstract][Full Text] [Related]
6. Radiographic severity and treatment outcome of Mycobacterium abscessus complex pulmonary disease.
Park J; Yoon SH; Kim JY; Gu KM; Kwak N; Yim JJ
Respir Med; 2021 Oct; 187():106549. PubMed ID: 34380092
[TBL] [Abstract][Full Text] [Related]
7.
Kwak N; Dalcolmo MP; Daley CL; Eather G; Gayoso R; Hasegawa N; Jhun BW; Koh WJ; Namkoong H; Park J; Thomson R; van Ingen J; Zweijpfenning SMH; Yim JJ
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 30880280
[TBL] [Abstract][Full Text] [Related]
8. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.
Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N
BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679
[TBL] [Abstract][Full Text] [Related]
10. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.
Park J; Cho J; Lee CH; Han SK; Yim JJ
Clin Infect Dis; 2017 Feb; 64(3):301-308. PubMed ID: 28011609
[TBL] [Abstract][Full Text] [Related]
11. Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis.
van Wijk F; Waterval J; van Aerde K; Henriet SSV; Meijer FJA; Borra LC; Aarnoutse RE; van Ingen J
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611360
[No Abstract] [Full Text] [Related]
12. Treatment outcome of continuation of intravenous amikacin for Mycobacterium abscessus pulmonary disease with a persistent culture positivity after the treatment initiation.
Park YE; Park SY; Jhun BW; Park Y; Kang YA; Park J; Kwak N; Yim JJ; Shim TS; Jo KW
J Infect Chemother; 2022 Aug; 28(8):1098-1104. PubMed ID: 35461769
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.
Koh WJ; Jeon K; Lee NY; Kim BJ; Kook YH; Lee SH; Park YK; Kim CK; Shin SJ; Huitt GA; Daley CL; Kwon OJ
Am J Respir Crit Care Med; 2011 Feb; 183(3):405-10. PubMed ID: 20833823
[TBL] [Abstract][Full Text] [Related]
14. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
[No Abstract] [Full Text] [Related]
15. Treatment of Mycobacterium abscessus Pulmonary Disease.
Griffith DE; Daley CL
Chest; 2022 Jan; 161(1):64-75. PubMed ID: 34314673
[TBL] [Abstract][Full Text] [Related]
16.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
[TBL] [Abstract][Full Text] [Related]
17. Chronic otitis media caused by Mycobacterium abscessus spp. massiliense treated with tigecycline in a 10-year-old child.
Myojin S; Fukuoka K; Kanemaru A; Baba S; Okamoto Y; Suzuki H; Kamada K; Yoshida A; Kikuchi K; Horikoshi Y
Int J Infect Dis; 2018 Sep; 74():10-12. PubMed ID: 29966711
[TBL] [Abstract][Full Text] [Related]
18. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections.
Jeong SH; Kim SY; Huh HJ; Ki CS; Lee NY; Kang CI; Chung DR; Peck KR; Shin SJ; Koh WJ
Int J Infect Dis; 2017 Jul; 60():49-56. PubMed ID: 28522316
[TBL] [Abstract][Full Text] [Related]
19. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
[TBL] [Abstract][Full Text] [Related]
20. [A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease].
Kassegne L; Veziris N; Fraisse P
Rev Mal Respir; 2024 Jan; 41(1):29-42. PubMed ID: 38016833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
